RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
Add like
Add dislike
Add to saved papers

Cicatricial pemphigoid, bullous pemphigoid, and epidermolysis bullosa acquisita antigens: differences in organ and species specificities and localization in chemically-separated human skin of three basement membrane antigens.

Bullous pemphigoid, cicatricial pemphigoid, and epidermolysis bullosa acquisita are three autoimmune diseases characterized by the presence of subepidermal blisters, in vivo-bound immunoreactants along the dermoepidermal junction, and variably detectable circulating anti-basement membrane autoantibodies. In order to better characterize the antigen(s) defined by cicatricial pemphigoid sera, indirect immunofluorescence was performed on a variety of human organs, skins of different animals, and on human skin chemically-split within the lamina lucida, comparing sera from cicatricial pemphigoid patients with sera from these two other blistering diseases. Sera from patients with each disease bound to the dermoepidermal junction of every laboratory animal species examined. In contrast, more mucosal tissues were bound by anti-basement membrane autoantibodies from patients with cicatricial pemphigoid and epidermolysis bullosa acquisita than from patients with bullous pemphigoid, consistent with the marked tendency for mucosal involvement in patients with the former two diseases. In addition, one of the cicatricial pemphigoid sera stained basal cell surfaces as well as dermoepidermal junction. Differences were also apparent in the staining of chemically-split human skin. The combined findings suggest that cicatricial pemphigoid and bullous pemphigoid antigens are distinct despite their common localization within the lamina lucida of the dermoepidermal junction. These data also suggest the presence of at least two different cicatricial pemphigoid antigens.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app